Aclaris Therapeutics
Stock Forecast, Prediction & Price Target
Aclaris Therapeutics (ACRS) stock Price Target by analysts
$6
Potential upside: 242.85%
Aclaris Therapeutics price prediction
What is Aclaris Therapeutics stock analysts` prediction?
Aclaris Therapeutics stock forecast: Based on 3 Wall Street analysts` predicted price targets for Aclaris Therapeutics in the last 3 months, the avarage price target is $6, with a high forecast of $NaN. The average price target represents a 242.85% change from the last price of $1.75.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Aclaris Therapeutics stock Price Target by analysts
Full breakdown of analysts given Aclaris Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Roger Song Jefferies | 0% 0/1 | 10 months ago | $7 300% upside | $3.14 | StreetInsider | Previous targets (0) |
Julian Harrison BTIG | 0% 0/1 | 10 months ago | $8 357.14% upside | $3.14 | StreetInsider | Previous targets (0) |
Alex Thompson Stifel Nicolaus | 0% 0/1 | 11 months ago | $3 71.42% upside | $2.28 | StreetInsider | Previous targets (0) |
Unknown Goldman Sachs | N/A | almost 3 years ago | $25 1328.57% upside | $15.22 | Benzinga | N/A |
Aclaris Therapeutics Financial Estimates
Aclaris Therapeutics Revenue Estimates
Aclaris Therapeutics EBITDA Estimates
Aclaris Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $6.76M N/A | $29.75M 340.05% | $31.24M 5.03% | Avg: $10.67M Low: $3.72M High: $17.24M avg. -65.82% | Avg: $7.56M Low: $3.42M High: $10.94M avg. -29.17% | Avg: $14.72M Low: $6.66M High: $21.30M avg. 94.61% | Avg: $37.49M Low: $16.97M High: $54.28M avg. 154.74% |
Net Income
% change YoY
| $-114.28M N/A | $-88.66M 22.41% | $-88.48M 0.20% | Avg: $-49.67M Low: $-94.24M High: $-30.01M avg. 43.85% | Avg: $-53.69M Low: $-87.26M High: $-25.82M avg. -8.09% | Avg: $-43.97M Low: $-69.57M High: $-12.69M avg. 18.09% | Avg: $-26.29M Low: $-41.59M High: $-7.58M avg. 40.21% |
EBITDA
% change YoY
| $-41.04M N/A | $-79.65M -94.07% | $-117.56M -47.58% | Avg: $-10.67M Low: $-17.24M High: $-3.72M avg. 90.91% | Avg: $-7.56M Low: $-10.94M High: $-3.42M avg. 29.17% | Avg: $-14.72M Low: $-21.30M High: $-6.66M avg. -94.61% | Avg: $-37.49M Low: $-54.28M High: $-16.97M avg. -154.74% |
EPS
% change YoY
| -$2.01 N/A | -$1.36 32.33% | -$1.27 6.61% | Avg: -$0.66 Low: -$1.35 High: -$0.43 avg. 48.22% | Avg: -$0.65 Low: -$1.25 High: -$0.37 avg. 1.14% | Avg: -$0.63 Low: -$1 High: -$0.18 avg. 3.07% | Avg: -$0.38 Low: -$0.6 High: -$0.11 avg. 40.21% |
Operating Expenses
% change YoY
| $67.43M N/A | $102.94M 52.66% | $130.79M 27.05% | Avg: $32.21M Low: $11.22M High: $52.01M avg. -75.36% | Avg: $22.81M Low: $10.33M High: $33.03M avg. -29.17% | Avg: $44.40M Low: $20.10M High: $64.28M avg. 94.61% | Avg: $113.12M Low: $51.22M High: $163.76M avg. 154.74% |
FAQ
What is Aclaris Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 23.51% in 2025-2028.
We have gathered data from 7 analysts. Their low estimate is -94.24M, average is -49.67M and high is -30.01M.
What is Aclaris Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 38.59% in 2025-2028.
We have gathered data from 7 analysts. Their low revenue estimate is $3.72M, average is $10.67M and high is $17.24M.
What is Aclaris Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 23.16% in 2025-2028.
We have gathered data from 7 analysts. Their low earnings per share estimate is -$1.35, average is -$0.66 and high is $-0.43.
What is the best performing analyst?
In the last twelve months 3 analysts have been covering Aclaris Therapeutics stock. The most successful analyst is Roger Song.